Alberto Falchetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5620928/publications.pdf

Version: 2024-02-01

161 papers 10,197 citations

50244 46 h-index 98 g-index

194 all docs

194 docs citations

194 times ranked 7524 citing authors

#	Article	IF	CITATIONS
1	Pathophysiology of Mild Hypercortisolism: From the Bench to the Bedside. International Journal of Molecular Sciences, 2022, 23, 673.	1.8	9
2	Energy Metabolism and Ketogenic Diets: What about the Skeletal Health? A Narrative Review and a Prospective Vision for Planning Clinical Trials on this Issue. International Journal of Molecular Sciences, 2021, 22, 435.	1.8	18
3	Hidden hypercortisolism: a too frequently neglected clinical condition. Journal of Endocrinological Investigation, 2021, 44, 1581-1596.	1.8	12
4	Early post-natal life stress induces permanent adrenocorticotropin-dependent hypercortisolism in male mice. Endocrine, 2021, 73, 186-195.	1.1	4
5	Cardiovascular complications of mild autonomous cortisol secretion. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101494.	2.2	21
6	Adenosine Deaminase 2 Deficiency: Its pleiotropic manifestations may also affect bone metabolism? A case study on two homozygous female twins. Bone Reports, 2021, 14, 101021.	0.2	0
7	Secondary prevention of fragility fractures: where do we stand during the COVID-19 pandemic?. Journal of Endocrinological Investigation, 2021, 44, 2521-2524.	1.8	6
8	Selenium: A Trace Element for a Healthy Skeleton - A Narrative Review. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 577-585.	0.6	13
9	Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary expert panel. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2210-2233.	1.1	7
10	A Novel Germline Mutation of ADA2 Gene in Two "Discordant―Homozygous Female Twins Affected by Adenosine Deaminase 2 Deficiency: Description of the Bone-Related Phenotype. International Journal of Molecular Sciences, 2021, 22, 8331.	1.8	1
11	What Do We Talk About When We Talk About Frailty?. Frontiers in Rehabilitation Sciences, 2021, 2, .	0.5	O
12	Metabolic Syndromes and Dysmobility. American Journal of Physical Medicine and Rehabilitation, 2021, 100, e32-e33.	0.7	4
13	Management and Medical Therapy of Mild Hypercortisolism. International Journal of Molecular Sciences, 2021, 22, 11521.	1.8	15
14	Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical Outcomes. Frontiers in Public Health, 2021, 9, 736665.	1.3	108
15	Management of Osteoporosis in Men: A Narrative Review. International Journal of Molecular Sciences, 2021, 22, 13640.	1.8	26
16	Metabolic syndrome and fragility fracture risk. Minerva Obstetrics and Gynecology, 2021, 73, 744-753.	0.5	1
17	Response to Letter to the Editor: "Methodological Issues Regarding Cortisol Secretion, Sensitivity, and Activity are Associated With Hypertension in Postmenopausal Eucortisolemic Womenâ€. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 376-377.	1.8	1
18	Defining Nonfunctioning Adrenal Adenomas on the Basis of the Occurrence of Hypocortisolism after Adrenalectomy. Journal of the Endocrine Society, 2020, 4, bvaa079.	0.1	9

#	Article	IF	CITATIONS
19	Idiopathic Osteoporosis and Nephrolithiasis: Two Sides of the Same Coin?. International Journal of Molecular Sciences, 2020, 21, 8183.	1.8	9
20	Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility. Journal of Diabetes Research, 2020, 2020, 1-18.	1.0	55
21	Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis. Expert Review of Endocrinology and Metabolism, 2020, 15, 283-298.	1.2	24
22	SUN-614 Prediction of Hypertension, Diabetes and Fractures in Eucortisolemic Women by Measuring Parameters of Cortisol Milieu. Journal of the Endocrine Society, 2020, 4, .	0.1	0
23	Emerging therapeutic targets for osteoporosis. Expert Opinion on Therapeutic Targets, 2020, 24, 115-130.	1.5	16
24	Prediction of hypertension, diabetes and fractures in eucortisolemic women by measuring parameters of cortisol milieu. Endocrine, 2020, 68, 411-419.	1.1	13
25	Treatment options for glucocorticoid-induced osteoporosis. Expert Opinion on Pharmacotherapy, 2020, 21, 721-732.	0.9	25
26	Bone metabolism, bone mass and structural integrity profile in professional male football players. Journal of Sports Medicine and Physical Fitness, 2020, 60, 912-918.	0.4	5
27	Phenotypes Associated With MEN1 Syndrome: A Focus on Genotype-Phenotype Correlations. Frontiers in Endocrinology, 2020, 11, 591501.	1.5	23
28	Calcium Citrate Versus Calcium Carbonate in the Management of Chronic Hypoparathyroidism: A Randomized, Double-Blind, Crossover Clinical Trial. Journal of Bone and Mineral Research, 2020, 37, 1251-1259.	3.1	6
29	Calcium citrate: from biochemistry and physiology to clinical applications. Reviews in Endocrine and Metabolic Disorders, 2019, 20, 353-364.	2.6	24
30	Cortisol Secretion, Sensitivity, and Activity Are Associated With Hypertension in Postmenopausal Eucortisolemic Women. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4441-4448.	1.8	18
31	Paget's Disease of Bone. Calcified Tissue International, 2019, 104, 483-500.	1.5	59
32	Hypovitaminosis D: Is It Time to Consider the Use of Calcifediol?. Nutrients, 2019, 11, 1016.	1.7	34
33	Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. Expert Opinion on Pharmacotherapy, 2019, 20, 805-811.	0.9	16
34	Mazabraud's Syndrome: A Case Report and Up-To-Date Literature Review. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2019, 19, 885-893.	0.6	10
35	DIAGNOSIS OF ENDOCRINE DISEASE: Evaluation of bone fragility in endocrine disorders. European Journal of Endocrinology, 2019, 180, R213-R232.	1.9	40
36	Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism. Journal of the American Geriatrics Society, 2018, 66, 518-524.	1.3	51

#	Article	IF	CITATIONS
37	Genetics of parathyroids disorders: Overview. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 781-790.	2.2	17
38	Management of familial hyperparathyroidism syndromes: MEN1, MEN2, MEN4, HPT-Jaw tumour, Familial isolated hyperparathyroidism, FHH, and neonatal severe hyperparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 861-875.	2.2	35
39	A novel germline mutation at exon 10 of MEN1 gene: a clinical survey and positive genotype-phenotype analysis of a MEN1 Italian family, including monozygotic twins. Hormones, 2018, 17, 427-435.	0.9	3
40	The interaction between vitamin C and bone health: a narrative review. Expert Review of Precision Medicine and Drug Development, 2018, 3, 215-223.	0.4	4
41	Italian Association of Clinical Endocrinologists (AME) and Italian Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical Management of Vitamin D Deficiency in Adults. Nutrients, 2018, 10, 546.	1.7	103
42	Mitochondriopathies and bone health. Trends in Biomedical Research, 2018, 1, .	0.2	5
43	Hereditary Hyperparathyroidism. , 2018, , 267-281.		0
44	Genetics of multiple endocrine neoplasia type 1 syndrome: what's new and what's old. F1000Research, 2017, 6, 73.	0.8	62
45	Vitamin K and bone metabolism: the myth and the truth. Expert Review of Precision Medicine and Drug Development, 2016, 1, 301-317.	0.4	5
46	Vitamin D and Bone Health. Food and Nutrition Sciences (Print), 2016, 07, 1033-1051.	0.2	0
47	SAT0284â€A Self-Administered Questionnaire May Allow General Practitioners to Perform a Rapid Screening to Identify Patients at Risk for Fragility Fractures and to Address Them to Bone Metabolism Specialized Clinical Centers. Annals of the Rheumatic Diseases, 2015, 74, 761.1-761.	0.5	0
48	SAT0285â€Application of Criteria for the Diagnosis of "Clinical Osteoporosis―in a Population of Postmenopausal Women from Emilia-Romagna Region. Annals of the Rheumatic Diseases, 2015, 74, 761.2-762.	0.5	0
49	Fragility fractures: clinical and therapeutic aspects. Journal of Biological Regulators and Homeostatic Agents, 2015, 29, 761-9.	0.7	1
50	Multiple Endocrine Neoplasia Type 1. Frontiers of Hormone Research, 2013, 41, 1-15.	1.0	55
51	A novel germline inactivating mutation in the CASR gene in an Italian kindred affected by familial hypocalciuric hypercalcemia. European Journal of Endocrinology, 2012, 166, 933-940.	1.9	4
52	The Regulatory Network Menin-MicroRNA 26a As a Possible Target for RNA-Based Therapy of Bone Diseases. Nucleic Acid Therapeutics, 2012, 22, 103-108.	2.0	35
53	Molecular diagnosis of parathyroid carcinoma: a reality in the near future. Expert Opinion on Medical Diagnostics, 2012, 6, 27-37.	1.6	4
54	Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Frontiers in Bioscience - Elite, 2011, E3, 364-370.	0.9	44

#	Article	IF	CITATIONS
55	Italian guidelines for the diagnosis and treatment of Paget's disease of bone. Reumatismo, 2011, 59, .	0.4	3
56	Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nature Genetics, 2011, 43, 685-689.	9.4	158
57	Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors. Clinical Cases in Mineral and Bone Metabolism, 2011, 8, 37-50.	1.0	1
58	Paget's disease of bone: there's more than the affected skeletal – a clinical review and suggestions for the clinical practice. Current Opinion in Rheumatology, 2010, 22, 410-423.	2.0	19
59	Genetic aspects of the Paget's disease of bone: concerns on the introduction of DNAâ€based tests in the clinical practice. Advantages and disadvantages of its application. European Journal of Clinical Investigation, 2010, 40, 655-667.	1.7	9
60	Ribozyme-mediated compensatory induction of menin-oncosuppressor function in primary fibroblasts from MEN1 patients. Cancer Gene Therapy, 2010, 17, 814-825.	2.2	18
61	Thyroid Cancer: Current Molecular Perspectives. Journal of Oncology, 2010, 2010, 1-17.	0.6	23
62	6. MEN syndromes. Tumori, 2010, 96, 823-826.	0.6	1
63	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. European Journal of Endocrinology, 2010, 163, 963.	1.9	1
64	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. European Journal of Endocrinology, 2010, 163, 301-308.	1.9	111
65	LRP5 gene polymorphism and cortical bone. Aging Clinical and Experimental Research, 2010, 22, 281-288.	1.4	1
66	Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how. F1000 Medicine Reports, 2010, 2, .	2.9	18
67	Giant cell tumor in a case of Paget's disease of bone: an aggressive benign tumor exhibiting a quick response to an innovative therapeutic agent. Clinical Cases in Mineral and Bone Metabolism, 2010, 7, 145-52.	1.0	6
68	MEN syndromes. Tumori, 2010, 96, 823-6.	0.6	0
69	A Novel Recessive Mutation of Fibroblast Growth Factor-23 in Tumoral Calcinosis. Journal of Bone and Joint Surgery - Series A, 2009, 91, 1190-1198.	1.4	31
70	Multiple Endocrine Neoplasia Type I Variants and Phenocopies: More than a Nosological Issue?. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1518-1520.	1.8	16
71	Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast–ovarian cancer syndromes: a case report. Cancer Genetics and Cytogenetics, 2009, 195, 75-79.	1.0	14
72	Infiltrating giant cell tumor in a case of Paget's disease of bone. Archives of Osteoporosis, 2009, 4, 91-94.	1.0	6

#	Article	IF	CITATIONS
73	Genetic Epidemiology of Paget's Disease of Bone in Italy: sequestosome1/p62 Gene Mutational Test and Haplotype Analysis at 5q35 in a Large Representative Series of Sporadic and Familial Italian Cases of Paget's Disease of Bone. Calcified Tissue International, 2009, 84, 20-37.	1.5	46
74	DNAâ€based test: when and why to apply it to primary hyperparathyroidism clinical phenotypes. Journal of Internal Medicine, 2009, 266, 69-83.	2.7	27
75	Characterization of a Non-UBA Domain Missense Mutation of Sequestosome 1 (SQSTM1) in Paget's Disease of Bone. Journal of Bone and Mineral Research, 2009, 24, 632-642.	3.1	48
76	Multiple endocrine neoplasia type 1 (MEN1): Not only inherited endocrine tumors. Genetics in Medicine, 2009, 11, 825-835.	1.1	89
77	Surgical Approach in Hereditary Hyperparathyroidism. Endocrine Journal, 2009, 56, 827-841.	0.7	41
78	Fisiopatologia e trattamento nelle forme familiari dell'Iperparatiroidismo Primitivo. Giornale De Techniche Nefrologiche & Dialitiche, 2009, 21, 18-24.	0.1	0
79	Aspetti epidemiologici della calcolosi di calcio in Italia: distribuzione dei fenotipi intermedi nella popolazione italiana. Giornale De Techniche Nefrologiche & Dialitiche, 2009, 21, 74-77.	0.1	0
80	Multiple Endocrine Neoplasia Type 1., 2009, , 1366-1368.		0
81	Genetica dell'osteoporosi, dell'osteopetrosi e dell'osteogenesi imperfetta. , 2009, , 255-265.		0
82	Polyostotic form of fibrous dysplasia in a 13 years old Colombian girl showing clinical and biochemical response to neridronate intravenous therapy. Clinical Cases in Mineral and Bone Metabolism, 2009, 6, 264-5.	1.0	5
83	Silent Familial Isolated Pituitary Adenomas: Histopathological and Clinical Case Report. Endocrine Pathology, 2008, 19, 40-46.	5.2	15
84	Multiple endocrine neoplasms. Best Practice and Research in Clinical Rheumatology, 2008, 22, 149-163.	1.4	37
85	Modulatory effect of farnesyl pyrophosphate synthase (<i>FDPS</i>) <i>rs2297480</i> polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. Current Medical Research and Opinion, 2008, 24, 2609-2615.	0.9	52
86	Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: The GENOMOS study. Bone, 2008, 42, 969-981.	1.4	91
87	The genetic ascertainment of multiple endocrine neoplasia type 1 syndrome by ancient DNA analysis. Journal of Endocrinological Investigation, 2008, 31, 905-909.	1.8	7
88	A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 351-357.	2.9	38
89	Multiple Endocrine Neoplasia Type 1., 2008, , 1345-1374.		4
90	Is Total Parathyroidectomy the Treatment of Choice for Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1?. Annals of Surgery, 2007, 246, 1075-1082.	2.1	78

#	Article	IF	Citations
91	Fokl Polymorphism of the Vitamin D Receptor Gene Correlates with Parameters of Bone Mass and Turnover in a Female Population of the Italian Island of Lampedusa. Calcified Tissue International, 2007, 80, 15-20.	1.5	20
92	Relationship of Volumetric Bone Mineral Density and Structural Parameters with ERÎ \pm Gene Polymorphisms. Calcified Tissue International, 2007, 80, 307-315.	1.5	7
93	The role of osteoprotegerin (OPG) and estrogen receptor (ER- $\hat{l}\pm$) gene polymorphisms in rheumatoid arthritis. Clinical Cases in Mineral and Bone Metabolism, 2007, 4, 156-60.	1.0	5
94	A novel polymorphism at the GNAS1 gene associated with low circulating calcium levels. Clinical Cases in Mineral and Bone Metabolism, 2007, 4, 139-45.	1.0	2
95	Thiazolidinediones and bone. Clinical Cases in Mineral and Bone Metabolism, 2007, 4, 103-7.	1.0	7
96	Rare Functioning Pancreatic Endocrine Tumors. Neuroendocrinology, 2006, 84, 189-195.	1.2	124
97	Multiple endocrine neoplasia type 1. Orphanet Journal of Rare Diseases, 2006, 1, 38.	1.2	129
98	Multiple endocrine neoplasia type 2. Orphanet Journal of Rare Diseases, 2006, 1, 45.	1.2	67
99	What Is the Relationship Between Paget's Disease of Bone and Hyperparathyroidism?. Journal of Bone and Mineral Research, 2006, 21, P69-P74.	3.1	13
100	MEN1 family with a novel frameshift mutation. Journal of Endocrinological Investigation, 2006, 29, 450-456.	1.8	9
101	Large-Scale Evidence for the Effect of the COLIA1 Sp1 Polymorphism on Osteoporosis Outcomes: The GENOMOS Study. PLoS Medicine, 2006, 3, e90.	3.9	160
102	Pancreatectomy in Multiple Endocrine Neoplasia Type 1-Related Gastrinomas and Pancreatic Endocrine Neoplasias. Annals of Surgery, 2006, 244, 61-70.	2.1	131
103	TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 395-401.	1.4	1,403
104	Gastrinoma (Duodenal and Pancreatic). Neuroendocrinology, 2006, 84, 173-182.	1.2	268
105	Well-Differentiated Gastric Tumors/Carcinomas. Neuroendocrinology, 2006, 84, 158-164.	1.2	133
106	Well-Differentiated Duodenal Tumor/Carcinoma (Excluding Gastrinomas). Neuroendocrinology, 2006, 84, 165-172.	1.2	70
107	Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma. Neuroendocrinology, 2006, 84, 196-211.	1.2	241
108	Poorly Differentiated Carcinomas of the Foregut (Gastric, Duodenal and Pancreatic). Neuroendocrinology, 2006, 84, 212-215.	1.2	106

#	Article	IF	CITATIONS
109	Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma. Neuroendocrinology, 2006, 84, 183-188.	1.2	248
110	Phytoestrogens: Food or Drug?., 2006,, 219-231.		0
111	Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience. Journal of Internal Medicine, 2005, 257, 38-49.	2.7	47
112	$\mathrm{ER}\hat{l}^2$ is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocrine-Related Cancer, 2005, 12, 455-469.	1.6	90
113	Thymic Neuroendocrine Carcinoma (Carcinoid) in Multiple Endocrine Neoplasia Type 1 Syndrome: The Italian Series. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2603-2609.	1.8	160
114	Lessons from genes mutated in multiple endocrine neoplasia (MEN) syndromes. Annales D'Endocrinologie, 2005, 66, 195-205.	0.6	12
115	Segregation of a M404V mutation of the p62/sequestosome 1 (p62/SQSTM1) gene with polyostotic Paget's disease of bone in an Italian family. Arthritis Research and Therapy, 2005, 7, R1289.	1.6	21
116	Calcium agonists in hyperparathyroidism. Expert Opinion on Investigational Drugs, 2004, 13, 229-244.	1.9	5
117	Genetics of Primary Hyperparathyroidism. Urologia Internationalis, 2004, 72, 11-16.	0.6	18
118	A Polymorphic CYP19 TTTA Repeat Influences Aromatase Activity and Estrogen Levels in Elderly Men: Effects on Bone Metabolism. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2803-2810.	1.8	151
119	Two Novel Mutations at Exon 8 of the Sequestosome 1 (SQSTM1) Gene in an Italian Series of Patients Affected by Paget's Disease of Bone (PDB). Journal of Bone and Mineral Research, 2004, 19, 1013-1017.	3.1	74
120	Azidothymidine Induces Apoptosis and Inhibits Cell Growth and Telomerase Activity of Human Parathyroid Cancer Cells in Culture. Journal of Bone and Mineral Research, 2004, 20, 410-418.	3.1	54
121	Calcium Bioavailability From a Calcium-Rich Mineral Water, With Some Observations on Method. Journal of Clinical Gastroenterology, 2004, 38, 761-766.	1.1	37
122	Influence of Calcium-Sensing Receptor Gene on Urinary Calcium Excretion in Stone-Forming Patients. Journal of the American Society of Nephrology: JASN, 2002, 13, 2517-2523.	3.0	135
123	Genetics of osteoporosis: role of steroid hormone receptor gene polymorphisms. Journal of Steroid Biochemistry and Molecular Biology, 2002, 81, 1-24.	1.2	83
124	Genetics of Osteoporosis. Medical Science Symposia Series, 2002, , 31-42.	0.0	0
125	Multiple Endocrine Neoplasia Type 1., 2002, , 1047-1066.		0
126	Genetic markers of osteoarticular disorders: facts and hopes. Arthritis Research, 2001, 3, 270.	2.0	31

#	Article	IF	CITATIONS
127	Microencapsulation of Human Parathyroid Cells: An "in Vitro―Study. Journal of Surgical Research, 2001, 96, 81-89.	0.8	24
128	CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5658-5671.	1.8	1,782
129	Somatic Mutation Analysis of the MEN1 Gene in Adrenocortical Tumors Using Denaturing Gradient Gel Electrophoresis (DGGE). International Journal on Disability and Human Development, 2001, 2, .	0.2	0
130	Polymorphism of the Aromatase Gene in Postmenopausal Italian Women: Distribution and Correlation with Bone Mass and Fracture Risk1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2263-2269.	1.8	93
131	CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5658-5671.	1.8	574
132	Polymorphism of the Aromatase Gene in Postmenopausal Italian Women: Distribution and Correlation with Bone Mass and Fracture Risk. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2263-2269.	1.8	74
133	Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. Human Molecular Genetics, 2000, 9, 2043-2050.	1.4	164
134	MEN1 gene mutation analysis in Italian patients with multiple endocrine neoplasia type 1. European Journal of Endocrinology, 2000, 142, 131-137.	1.9	42
135	Fokl Polymorphism at Translation Initiation Site of the Vitamin D Receptor Gene Predicts Bone Mineral Density and Vertebral Fractures in Postmenopausal Italian Women. Journal of Bone and Mineral Research, 1999, 14, 1379-1386.	3.1	94
136	Telomerase Repeat Amplification Protocol (TRAP): A New Molecular Marker for Parathyroid Carcinoma. Biochemical and Biophysical Research Communications, 1999, 265, 252-255.	1.0	23
137	Genetics of Osteoporosis., 1999,, 117-124.		0
138	Allelic Variants of Human Calcitonin Receptor: Distribution and Association with Bone Mass in Postmenopausal Italian Women. Biochemical and Biophysical Research Communications, 1998, 245, 622-626.	1.0	51
139	Polymorphisms of the Calcitonin Receptor Gene Are Associated with Bone Mineral Density in Postmenopausal Italian Women. Biochemical and Biophysical Research Communications, 1998, 248, 190-195.	1.0	90
140	Genetic testing for multiple endocrine neoplasias. Endocrine-Related Cancer, 1998, 5, 37-44.	1.6	1
141	Allelic Loss in Parathyroid Tumors from Individuals Homozygous for Multiple Endocrine Neoplasia Type 11. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2278-2282.	1.8	9
142	HPE Cells: A Clonal Endothelial Cell Line Established From Human Parathyroid Tissue (Human) Tj ETQq0 0 0 rgBT	/Oyerlock 1.7	10 ₄ Tf 50 142
143	Aggressive Forms of Gastric Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type I. American Journal of Surgical Pathology, 1997, 21, 1075-1082.	2.1	102
144	Allelic Loss in Parathyroid Tumors from Individuals Homozygous for Multiple Endocrine Neoplasia Type 1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2278-2282.	1.8	8

#	Article	IF	Citations
145	Characterization and function of the receptor for IGF-I in human preosteoclastic cells. Bone, 1996, 18, 269-276.	1.4	46
146	Clonal Analysis by Chromosome 11 Microsatellite-PCR of Microdissected Parathyroid Tumors from MEN 1 Patients. Biochemical and Biophysical Research Communications, 1996, 227, 736-742.	1.0	8
147	Steroid 5α-reductase 2 deficiency: virilization in early infancy may be due to partial function of mutant enzyme. Clinical Endocrinology, 1996, 44, 477-482.	1.2	24
148	Lack of allelic loss at the multiple endocrine neoplasia type 1(MEN-1) gene locus in a pancreatic ductal (non-endocrine) adenocarcinoma of a patient with the MEN-1 syndrome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1995, 426, 203-8.	1.4	7
149	RFLP Analysis of Human Chromosome 11 Region $q13$ in Multiple Symmetrical Lipomatosis and Multiple Endocrine Neoplasia Type 1 -Associated Lipomas. Biochemical and Biophysical Research Communications, $1995, 207, 363-368$.	1.0	29
150	Evidence for Bioeffects of LY 139478 on the Human Preosteoclastic Cell Line FLG 29.1. Biochemical and Biophysical Research Communications, 1995, 211, 857-863.	1.0	6
151	Genetic screening to identify the gene carrier in Italian and German kindreds affected by multiple endocrine neoplasia type 1 (MEN 1) syndrome. Journal of Endocrinological Investigation, 1995 , 18 , $329-335$.	1.8	6
152	Relaxin influences growth, differentiation and cell-cell adhesion of human breast-cancer cells in culture. International Journal of Cancer, 1994, 57, 129-134.	2.3	58
153	Production of basic fibroblast growth factor by gastric carcinoid tumors and their putative cells of origin. Human Pathology, 1994, 25, 175-180.	1.1	51
154	Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11 Journal of Clinical Endocrinology and Metabolism, 1993, 76, 139-144.	1.8	95
155	Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. Journal of Clinical Endocrinology and Metabolism, 1993, 76, 139-144.	1.8	86
156	Homozygotes for the autosomal dominant neoplasia syndrome (MEN1). American Journal of Human Genetics, 1993, 53, 1167-72.	2.6	27
157	Clonality of Parathyroid Tumors in Familial Multiple Endocrine Neoplasia Type 1. New England Journal of Medicine, 1989, 321, 213-218.	13.9	315
158	Echocardiographic Evaluation of Children with and without Family History of Essential Hypertension. American Journal of Hypertension, 1988, 1, 305-308.	1.0	30
159	Vitamin D Status and SARS-CoV2 Clinical Outcomes: A Systematic Review and Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	1
160	MEN syndromes. Endocrine Abstracts, 0, , .	0.0	0
161	Cortisol suppression or peripheral sensitivity and activation are associated with diabetes, hypertension and fragility fractures in postmenopausal eucortisolemic women. Endocrine Abstracts, 0, , .	0.0	0